Molecular Marker Discovery and Evaluation: EGF rs1897990 and rs1524106 Variants in a China Lung Adenocarcinoma Young Population
Related Experiment Video
Updated: Jul 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Huiwen Pan1, Xiangyang Wang1, Lijie Zheng1
1The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Objective:
The objective of this study is to investigate the genetic susceptibility and risk factors of EGF gene rs1897990 and rs1524106 in lung adenocarcinoma young patients aged ≤ 45 years.
Methods:
A case-control study was conducted. DNA was extracted and identified from 88 samples from case and control groups by single-nucleotide polymorphism assay. PCR amplification was performed by TaqMan probe method, and the factors of smoking, drinking, sex, and age were also included. To investigate the clinical factors and genotyping differences between case and control groups.
Results:
Smoking was an influential factor in young lung adenocarcinoma patients. The mutation frequency of EGF gene rs1897990 CT heterozygous mutant was different between the two groups (p = 0.021). The T alleles of EGF rs1897990 and rs1524106 were significantly different between the two groups (p = 0.034 and p = 0.023).
Conclusions:
The young lung adenocarcinoma population (≤ 45 years old) is susceptible to EGF rs1897990 and rs1524106 variants, with smoking being another risk factor. Additionally, smoking may enhance the risk of EGF rs1897990 and rs1524106 variants threatening the development of lung adenocarcinoma.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets